HB 645 (2025)

Requires reports issued by the Prescription Drug Affordability Board to describe the source of the data, encourages the use of memorandums of understanding between the Board and state agencies regarding data collection, and directs the Board to use data gathered by other agencies or entities whenever feasible to meet reporting requirements.  The bill also repeals certain drug price notification, confidentiality, and registration requirements.  Lastly, the bill defines "data steward" for purposes of such data collection.